What TSH tells a provider
Thyroid-stimulating hormone helps regulate the thyroid's hormone production. Testing can help identify an underactive or overactive thyroid, and additional tests may be needed to understand an abnormal result.[1]
Symptoms such as fatigue or weight change may lead a provider to consider thyroid testing. They do not make TSH a test of whether a weight-management medication is suitable.
What the boxed warning says
The approved semaglutide and tirzepatide labels describe thyroid C-cell tumors in rodents. Whether these medications cause such tumors in humans is unknown. Both products are contraindicated in people with a personal or family history of MTC or with multiple endocrine neoplasia syndrome type 2, known as MEN 2.[2][3]
That history needs to be discussed directly. If a relative had thyroid cancer and the type is unclear, explain that uncertainty rather than assuming it is or is not relevant.
Bring the diagnosis, if available
Useful information includes the name of a past thyroid diagnosis, relevant reports, current medicines and any known family history. “Thyroid disease” is a broad description; the specific condition helps the provider interpret it.
The semaglutide label also advises reporting a neck lump, persistent hoarseness, swallowing difficulty or breathing difficulty. It states that routine calcitonin testing or thyroid ultrasound has uncertain value for early detection of MTC during treatment.[2]
